World ADC 2019: Maximizing the Clinical Therapeutic Index of Antibody-drug Conjugates
With five approved and commercially available antibody-drug conjugates and nearly 100 in various stages of clinical development, it is...
Transparency, Openness and a Consumer-Focused Approach are Musts in the Murky World of Drug...
As we head into another election cycle, voters across the country can be assured that health care and the...
Personalizing Cancer Treatment: Why Adaptive Therapy Isn’t There Yet
Oh, how far we’ve come! When we take a holistic look at the major milestones and obstacles in cancer care...
Understanding of the Underlying Mechanisms of Target-Independent Uptake and Toxicity
With 4 approved agents, antibody-drug conjugates or ADC have shown to be a very promising class of therapeutics. While the...
In the War Against Brain Cancer, Accelerated Clinical Trials Are a Crucial Strategy
More than 1.4 million people live with malignant brain tumors. Glioblastoma – the cancer that killed Senators John McCain...
How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?
In the aftermath of the fall of renowned breast cancer researcher Jose Baselga, MD, PhD, following revelations last month...
Benefitting from the Worldwide Supply Chain in the development of Antibody-drug Conjugates
Timing is everything. Just over a decade ago, the pharmaceutical industry and R&D in China was dominated by generics and...
Eric Rosenthal Reports | A Personal Remembrance of Two Giants of Oncology: Jim...
James F. Holland, MD, one of the pioneers of combination chemotherapy and cancer cooperative group research, died at the...
PepTalk: The Protein Science Week – New Horizons, New Goals
This year PepTalk: The Protein Science Week, one of the largest annual gatherings of protein science researchers in the...
Moving Ahead: More ADC Progressing Through the Clinic and Beyond Oncology and Hematology
This week from September 20-22, 2017, the 8th World ADC, the industry’s leading forum, discussing the latest developments and...
